Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).
暂无分享,去创建一个
[1] W. Garvey,et al. Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction. , 2006, Biochemistry.
[2] N. Richards,et al. Novel agouti-related-protein-based melanocortin-1 receptor antagonist. , 2001, Journal of medicinal chemistry.
[3] M. Bednarek,et al. Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Journal of medicinal chemistry.
[4] Paolo Grieco,et al. Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. , 2002, Journal of medicinal chemistry.
[5] R. Mains,et al. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. , 1980, Endocrine reviews.
[6] J. Funder,et al. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. , 1988, Endocrine reviews.
[7] L. Chen,et al. Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: arginine substitution. , 2002, Bioorganic & medicinal chemistry letters.
[8] Y. Wan,et al. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. , 2001, Biochemistry.
[9] V J Hruby,et al. alpha-Melanotropin: the minimal active sequence in the frog skin bioassay. , 1987, Journal of medicinal chemistry.
[10] P. Grieco,et al. Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. , 2002, Biochemical and biophysical research communications.
[11] R. Cone,et al. A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. , 1995, Analytical biochemistry.
[12] A. Lerner,et al. Effect of Alpha- and Beta-Melanocyte Stimulating Hormones on the Skin Colour of Man , 1961, Nature.
[13] A. Edison,et al. Incorporation of a bioactive reverse-turn heterocycle into a peptide template using solid-phase synthesis to probe melanocortin receptor selectivity and ligand conformations by 2D 1H NMR. , 2011, Journal of medicinal chemistry.
[14] W. Millard,et al. Implication of the melanocortin-3 receptor in the regulation of food intake. , 2011, European journal of pharmacology.
[15] B. Schölkens,et al. ACTH and alpha-MSH: cardiovascular and antiarrhythmic properties. , 1974, Archives internationales de pharmacodynamie et de therapie.
[16] C. Haskell-Luevano,et al. Structure–activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors Part 3: modifications at the Arg position , 2003, Peptides.
[17] Ximena Opitz-Araya,et al. Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides , 1997, Cell.
[18] Jinfa Ying,et al. Solution structures of cyclic melanocortin agonists and antagonists by NMR. , 2003, Biopolymers.
[19] M. Bednarek,et al. Structure-function studies on the cyclic peptide MT-II, lactam derivative of α-melanotropin☆ ☆ Throughout this report, the numbering of the amino acid residues in α-MSH has been retained for all linear and cyclic peptides. , 1999, Peptides.
[20] M. Meldal,et al. A solid-phase approach to mouse melanocortin receptor agonists derived from a novel thioether cyclized peptidomimetic scaffold. , 2002, Journal of the American Chemical Society.
[21] Xin-jie Chu,et al. Structure–activity relationship of cyclic peptide penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH2 at the human melanocortin-1 and -4 receptors: His6 substitution , 2003 .
[22] M. Tota,et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. , 2000, Biochemistry.
[23] Xin-jie Chu,et al. Structure-activity relationship of linear peptide Bu-His6-DPhe7-Arg8-Trp9-Gly10-NH2 at the human melanocortin-1 and -4 receptors: DPhe7 and Trp9 substitution. , 2003, Bioorganic & medicinal chemistry letters.
[24] C. Haskell-Luevano,et al. Melanocortin Ligands: 30 Years of Structure—Activity Relationship (SAR) Studies , 2004 .
[25] N. Rowland,et al. Effect of MTII on food intake and brain c-Fos in melanocortin-3, melanocortin-4, and double MC3 and MC4 receptor knockout mice , 2010, Peptides.
[26] J. Baik,et al. Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues. , 1999, European journal of biochemistry.
[27] R. Cone,et al. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat , 2001, Nature Neuroscience.
[28] V. Hruby,et al. [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[29] T. Kucharzik,et al. Role of the Melanocortin System in Inflammation , 2006, Annals of the New York Academy of Sciences.
[30] G. Rose,et al. Turns in peptides and proteins. , 1985, Advances in protein chemistry.
[31] Zhimin Xiang,et al. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position. , 2002, Journal of medicinal chemistry.
[32] P. Grieco,et al. Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. , 2003, The journal of peptide research : official journal of the American Peptide Society.
[33] M. Bednarek,et al. 1H‐NMR studies on a potent and selective antagonist at human melanocortin receptor 4 (hMC‐4R) , 2003, Biopolymers.
[34] Richard P. Woychik,et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.
[35] V. Hruby,et al. Design of potent linear α-melanotropin 4-10 analogues modified in positions 5 and 10 , 1989 .
[36] V. Hruby,et al. Melanotropins structural conformational and biological considerations in the development of superpotent and superprolonged analogs , 1984 .
[37] Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Biochemical and biophysical research communications.
[38] R. Petrovska,et al. Melanocortin receptors form constitutive homo- and heterodimers. , 2005, Biochemical and biophysical research communications.
[39] E. Kaiser,et al. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.
[40] M. Mortrud,et al. The cloning of a family of genes that encode the melanocortin receptors. , 1992, Science.
[41] C. Pouton,et al. Synthesis and biological evaluation of α-MSH analogues substituted with alanine , 1994, Peptides.
[42] David C Fry,et al. A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides. , 2004, Bioorganic & medicinal chemistry.
[43] Andrzej Wilczynski,et al. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. , 2004, Journal of medicinal chemistry.
[44] B D Sykes,et al. Chemical shifts as a tool for structure determination. , 1994, Methods in enzymology.
[45] Xin-jie Chu,et al. Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH(2) at the human melanocortin-1 and -4 receptors: histidine substitution. , 2002, Bioorganic & medicinal chemistry letters.
[46] C. Humblet,et al. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. , 1996, Drug design and discovery.
[47] M. Tschöp,et al. MC4R Dimerization in the Paraventricular Nucleus and GHSR/MC3R Heterodimerization in the Arcuate Nucleus: Is There Relevance for Body Weight Regulation? , 2012, Neuroendocrinology.
[48] L. Hakim. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind placebo controlled crossover study , 1999, International Journal of Impotence Research.
[49] M. Bednarek,et al. Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5. , 1999, Biochemical and biophysical research communications.
[50] R. Fillingim,et al. Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans , 2005, Journal of Medical Genetics.
[51] Zhimin Xiang,et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. , 2008, Journal of medicinal chemistry.
[52] L. Stewart,et al. The Melanocortin 3 Receptor: A Novel Mediator of Exercise-Induced Inflammation Reduction in Postmenopausal Women? , 2011, Journal of aging research.
[53] V. Hruby,et al. Design of Peptides, Proteins, and Peptidomimetics in Chi Space , 1997 .
[54] M. Bogyo,et al. Novel Aza Peptide Inhibitors and Active‐Site Probes of Papain‐Family Cysteine Proteases , 2006, Chembiochem : a European journal of chemical biology.
[55] S. Watson,et al. Molecular cloning of a novel melanocortin receptor. , 1993, The Journal of biological chemistry.
[56] C. Haskell-Luevano,et al. Design and pharmacology of peptoids and peptide-peptoid hybrids based on the melanocortin agonists core tetrapeptide sequence. , 2003, Bioorganic & medicinal chemistry letters.
[57] V. Hruby,et al. Design of a New Class of Superpotent Cyclic α-Melanotropins Based on Quenched Dynamic Simulations. , 1989 .
[58] R. Cone,et al. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. , 1995, Journal of medicinal chemistry.
[59] V. Hruby,et al. 4-Norleucine , 7D-phenylalanine-a-melanocyte-stimulating hormone : A highly potent a-melanotropin with ultralong biological activity ( amino acid racemization / peptide degradation / adenylate cyclase / tyrosinase / melanoma ) , 2022 .
[60] I. Pogozheva,et al. Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity. , 2008, Journal of medicinal chemistry.
[61] M. Mortrud,et al. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. , 1994, Molecular endocrinology.
[62] V. Hruby,et al. Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. , 2010, Journal of the American Chemical Society.
[63] G. Gessa,et al. Induction of Sexual Excitement by the Action of Adrenocorticotrophic Hormone in Brain , 1969, Nature.
[64] V. Hruby,et al. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. , 1989, Journal of medicinal chemistry.
[65] H. Schild. pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM , 1997, British journal of pharmacology and chemotherapy.
[66] V. Hruby,et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[67] Yue Feng,et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.
[68] V. Hruby,et al. beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity. , 1997, Journal of medicinal chemistry.
[69] G. Barsh,et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.
[70] C. Haskell-Luevano,et al. Synthesis and activity of the melanocortin Xaa-d-Phe-Arg-Trp-NH tetrapeptides with amide bond modifications. , 2004, The journal of peptide research : official journal of the American Peptide Society.
[71] J. Hoyer,et al. Modulation of blood pressure by central melanocortinergic pathways. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[72] Hongmao Sun,et al. Highly Selective Cyclic Peptides for Human Melanocortin-4 Receptor (MC-4 R): Design, Synthesis, Bioactive Conformation, and Pharmacological Evaluation as an Anti-Obesity Agent , 2001 .
[73] C. Haskell-Luevano,et al. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position. , 2002, Journal of medicinal chemistry.
[74] H. Schiöth,et al. Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119 , 1999, Neuropeptides.
[75] J. Wikberg,et al. Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. , 1998, Endocrinology.
[76] Jinfa Ying,et al. Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues selective for the human melanocortin-4 receptor. , 2006, Journal of medicinal chemistry.
[77] Xin-jie Chu,et al. Structure-activity relationship of cyclic peptide penta-c[Asp-His(6)-DPhe(7)-Arg(8)-Trp(9)-Lys]-NH(2) at the human melanocortin-1 and -4 receptors: His(6) substitution. , 2003, Bioorganic & medicinal chemistry letters.
[78] Michael G Kelly,et al. Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2). , 2003, Bioorganic & medicinal chemistry letters.
[79] V. Hruby,et al. NMR and quenched molecular dynamics studies of superpotent linear and cyclic α-melanotropins , 2009 .
[80] M. Mortrud,et al. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[81] W. Elliott. Modulation of Blood Pressure by Central Melanocortinergic Pathways , 2010 .
[82] A. Catania. The melanocortin system in leukocyte biology , 2007, Journal of leukocyte biology.
[83] J. Wikberg,et al. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA , 1992, FEBS letters.
[84] J. Wikberg,et al. Molecular cloning of a novel human melanocortin receptor. , 1993, Biochemical and biophysical research communications.
[85] W. Millard,et al. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms. , 2007, Biochemistry.
[86] Victor J. Hruby,et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.
[87] S. Watson,et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. , 1993, The Journal of biological chemistry.
[88] G. Han,et al. 9-Fluorenylmethoxycarbonyl amino-protecting group , 1972 .
[89] C. Haskell-Luevano,et al. Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors: part 2 modifications at the Phe position. , 2002, Journal of medicinal chemistry.
[90] G. Han,et al. 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group , 1970 .
[91] R. Woychik,et al. Molecular characterization of the mouse agouti locus , 1992, Cell.
[92] C. Haskell-Luevano,et al. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor , 2001, Regulatory Peptides.
[93] T. Schöneberg,et al. Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin- and melanocortin-3 receptors , 2012 .
[94] B. Pettitt,et al. Modeling of alpha-MSH conformations with implicit solvent. , 1999, The journal of peptide research : official journal of the American Peptide Society.
[95] Y. Konda,et al. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. , 1994, Biochemical and biophysical research communications.
[96] Andrzej Wilczynski,et al. Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 peptide template. , 2005, Journal of medicinal chemistry.
[97] V. Hruby,et al. Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. , 1995, Journal of Medicinal Chemistry.